Clinical Research Division, Fred Hutch Cancer Center, Seattle, Washington, USA; Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Department of Pediatrics, University of Washington, Seattle, Washington, USA; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.
Semin Hematol. 2024 Oct;61(5):314-320. doi: 10.1053/j.seminhematol.2024.08.004. Epub 2024 Aug 22.
Treatment with CD19-targeted chimeric antigen receptor T cell therapy (CD19-CART) has improved salvage rates in children and adults with relapsed and/or refractory B-cell acute lymphoblastic leukemia (ALL). However, not all patients treated with CD19-CAR T cells achieve long-term remission. The role of allogeneic hematopoietic stem cell transplantation as consolidative therapy remains undefined. We aim to review the current literature published to date regarding prognostic markers indicating durable ALL response to CD19-CART and risk factors for relapse after CD19-CART to identify patient cohorts who may benefit from consolidative hematopoietic stem cell transplantation.
CD19 靶向嵌合抗原受体 T 细胞疗法（CD19-CART）的治疗提高了复发和/或难治性 B 细胞急性淋巴细胞白血病（ALL）患儿和成人的挽救率。然而，并非所有接受 CD19-CAR T 细胞治疗的患者都能获得长期缓解。异基因造血干细胞移植作为巩固治疗的作用仍未确定。我们旨在回顾迄今为止发表的关于预示 CD19-CART 治疗后 ALL 持续缓解的预后标志物和 CD19-CART 后复发风险因素的现有文献，以确定可能从巩固性造血干细胞移植中获益的患者群体。
